ロード中...

Combined inhibition of PI3K and Src kinases demonstrates synergistic therapeutic efficacy in clear-cell renal carcinoma

Potent inhibitors of PI3K (GDC-0941) and Src (Saracatinib) exhibit as individual agents, excellent oral anticancer activity in preclinical models and have entered phase II clinical trials in various cancers. We found that PI3K and Src kinases are dysregulated in clear cell renal carcinomas (ccRCCs),...

詳細記述

保存先:
書誌詳細
出版年:Oncotarget
主要な著者: Roelants, Caroline, Giacosa, Sofia, Pillet, Catherine, Bussat, Rémi, Champelovier, Pierre, Bastien, Olivier, Guyon, Laurent, Arnoux, Valentin, Cochet, Claude, Filhol, Odile
フォーマット: Artigo
言語:Inglês
出版事項: Impact Journals LLC 2018
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6059021/
https://ncbi.nlm.nih.gov/pubmed/30046388
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25700
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!